

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

SEQ ID NO.: 1

```

HGEFTFTSDVSSYLEGQAAKEFIAWLVKGRHGEFTFTSDVSSYLEGQAAKEFIAWLVKGR 60
DAHKSEVAHRFKDLGEENFKALVLI AFAQYLQQCPFEDHVKLVNEVTEFAKTCVADES AE 120
NCDKSLHTL FGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPE 180
VDVMCTAFHDNEETFLKKYLYEIAARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLL 240
PKLDEL RDEGKASSAKQRLK CASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLT 300
KVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMP 360
ADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVLLLLRLAKTYETTLEK 420
CCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCLEFEQLGEYKFQNALLVRYTKKVPQVS 480
TPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTE 540
SLVNR RPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKA 600
TKEQLKAVMDDFAAFVEKCKADDKETCFAEEGKKLVAASQAALGL 674

```

Figure 6




Figure 7




Figure 8

SEQ ID NO: 3 anti-NOGO mAb Heavy chain

MGWSCIILFL VATATGVHSQ VQLVQSGAEV KKPASVKVS CKASGYTFTS YWMHWVRQAP
GQGLEWIGNI NPSNGGTNYN EKFKSKATMT RDTSTSTAYM ELSSLRSEDV AVYYCELMQG
YWGQGTLLTV SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS
GVHTFPAVLQ SSGLYSLSSV VTPVSSSLGT QTYICNVNHK PSNTKVDKKV EPKSCDKTHT
CPPCPAPELA GAPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH
NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE
PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTP PVLDSDGSFF
LYSKLTVDKS RWQQGNVFSC SVMHEALHNN YTQKSLSLSP GK

SEQ ID NO: 4 anti-NOGO mAb light chain

MGWSCIILFL VATATGVHSD IVMTQSPLSN PVTLGQPVSI SCRSSKSLLY KDGKTYLNWF
LQRPQGSPQL LIYLMSTRAS GVPDRFSGGG SGTDFTLKIS RVEAEDVGVY YCQQLVEYPL
TFGQGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS
GNSQESVTEQ DSKDSTYSLV STLTLKADY EKHKVYACEV THQGLSSPVT KSFNRGEC

Figure 9

SEQ ID NO: 5 anti-TNFR1 dAb

EVQLLES GGG LVQPGGSLRL SCAASGFTFA HETMVWVRQA PGKGLEWVSH IPPDGQDPFY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYHCALLP KRGPWFYDWG QGTLVTVSS

5

Figure 10

SEQ ID NO: 6 IL18

YFGKLESKLS VIRNLNDQVL FIDQGNRPLF EDMTDSDCRD NAPRTIFIIS

MYKDSQPRGM AVTISVKCEK ISTLSCENKI ISFKEMNPPD NIKDTKSDII

FFQRSVPGHD NKMQFESSY EGYFLACEKE RDLFKLILKK EDELGDRSIM

FTVQNE

Figure 11

SEQ ID NO: 7 anti-IL5 mAb Heavy chain

QVTLRESGPA LVKPTQTLTL TCTVSGFSLT SYSVHWVRQP PGKGLEWLGV
IWASGGTDYN SALMSRLSIS KDTSRNQVVL TMTNMDPVDV ATYYCARDPP
SSLLRLDYWG RGTPVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD
YFPEPVTVSW NSGALTSGVH TFPVQLQSSG LYSLSVVTV PSSSLGTQTY
ICNVNHHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK

SEQ ID NO: 8 anti-IL5 mAb light chain

DIVMTQSPDS LAVSLGERAT INCKSSQSLL NSGNQKNYLA WYQQKPGQPP
KLLIYGASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQNVHSF
PFTFGGGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEEKHKVYAC
EVTHQGLSSP VTKSFNRGEC

Figure 12

SEQ ID NO: 9 anti-CD20 VH

MFLGLSWIFL LAILKGVQCE VQLVESGGGL VPQGRSLRLS CAASGFTFND
YAMHWVRQAP GKGLEWVSTI SWNSGSIGYA DSVKGRFTIS RDNAKKSLEYL
QMNSLRAEDT ALYYCAKDIQ YGNYYYGMDV WGQGTTVTVS S

SEQ ID NO: 10 anti-CD20 VL

MEAPAQLLFL LLLWLPDTTG EIVLTQSPAT LSLSPGERAT LSCRASQSVS
SYLAWYQQKP GQAPRLLIYD ASNRATGIPA RFSGSGSGTD FTLTISSLEP
EDFAVYYCQQ RSNWPITFGQ GTRLEIK